Thrombosis and malignancy: An underestimated problem

Haematologica

Volumn 88, Issue 6, 2003, Pages 607-610

  Falanga, Anna ^a  

^a OSPEDALI RIUNITI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; ANTINEOPLASTIC AGENT; TAMOXIFEN;

CANCER CHEMOTHERAPY; CLINICAL FEATURE; DISEASE ASSOCIATION; HUMAN; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; OCCULT CANCER; PANCREAS CANCER; POSTOPERATIVE COMPLICATION; RECURRENT DISEASE; REVIEW; STOMACH CANCER; THROMBOEMBOLISM; THROMBOGENESIS; THROMBOSIS;

HUMANS; NEOPLASMS; RECURRENCE; RISK FACTORS; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 0037789215     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (15)

1. Trousseau A. Phlegmasia alba dolens; in: Clinique medicale de l'Hotel-Dieu de Paris. Paris, JB Balliere et Fils, 1865; vol 3. p. 654-712.
2. Billroth T. Lectures on surgical pathology and therapeutics: a handbook for students and practitioners. Translated from the 8th ed, London, The New Sydenham Society 1877-1878.
3. Rickles FR, Falanga A. Molecular basis for the relationship between cancer and thrombosis. Thromb Res 2001;102:V 215-24.
4. Piccioli A, Prandoni P. Venous thromboembolism as first manifestation of cancer. Acta Haematol 2001;106:13-7.
5. Prandoni P, Lensing AW, Buller HR, Cogo A, Prins MH, Cattelan AM, et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. New Engl J Med 1992;327:1128-33.
6. Schulman S, Lindmarker P. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. N Engl J Med 2000;342:1953-8.
7. Rickles FR, Levine M, Dvorak HB. Abnormalities of Hemostasis in Malignancy, in: Colman RW, Hirsh J, Marder VJ, Clowes A, George JN, Editors. Hemostasis and Thrombosis. Philadelphia, Lippincott Williams Et Wilkins; 2000, Chapter 69. p. 1132-52.
8. Levine MN. Prevention of thrombotic disorders in cancer patients undergoing chemotherapy. Thromb Haemost 1997;78: 133-6.
9. Bona RD. Thrombotic complications of central venous catheters in cancer patients. Semin Thromb Hemost 1999;25:147-55.
10. Thodiyil PA, Walsh DC, Kakkar AK. Thromboprophylaxis in the cancer patient. Acta Haematol 2001;106:73-80.
11. Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, et al. A comparison of low molecular weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep vein thrombosis. N Eng J Med 1996;334:677-81.
12. Prandoni P, Lensing AW, Cogo A, Cuppini S, Villalta S, Carta M, et al. The long-term clinical course of acute deep venous thrombosis. Ann Int Med 1996;125:1-7.
13. Hutten BA, Prins MH, Gent M, Ginsberg J, Tijssen J, Buller HR. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved International Normalized Ratio: a retrospective analysis. J Clin Oncol 2000;18:3078-83.
14. Palareti G, Legnani C, Lee A, Manotti C, Hirsh J, D'Angelo D, et al. A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy. Thromb Haemost 2000; 84:805-10.
15. Prandoni P, Lensing AW, Piccioli A, Bernardi E, Simioni P, Girolami B, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002;100:3484-8.